Loading clinical trials...
Loading clinical trials...
A Multi-Center, Randomized, Parallel, Double-Blind, Placebo-Controlled Study in Evaluation the Efficacy and Safety of Laxymig® ER as Prophylactic Treatment in Patients With Migraine
The purpose of this study is to evaluate the efficacy and safety of Laxymig® ER compared with placebo in prophylactic monotherapy treatment of migraine headache.
The purpose of this study is to evaluate the efficacy and safety of Laxymig® ER compared with placebo in prophylactic monotherapy treatment of migraine headache. Four weeks baseline, following with 12 weeks treatment phase. Subjects migraine are recorded by diary cards and re-evaluated by the investigator. Subject will have visit every 4-week (+/- 7 days).
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Changhua Christian Hospital
Changhua, Taiwan
Chung-Ho Memorial Hospital, Kaohsiung Medical University
Kaohsiung City, Taiwan
Chang-Gung Memorial Hospital
Linkou District, Taiwan
Chinese Medical University Hospital
Taichung, Taiwan
SinLau Christian Hospital
Tainan, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
Taipei Medical University Hospital
Taipei, Taiwan
Start Date
November 1, 2004
Completion Date
September 1, 2006
Last Updated
September 10, 2007
74
ACTUAL participants
Laxymig ER (drug)
DRUG
Lead Sponsor
Lotus Pharmaceutical
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07342296